公开(公告)号：US20250066422A1

公开(公告)日：2025-02-27

申请号：US18936387

申请日：2024-11-04

Applicant: Immatics Biotechnologies GmbH

Inventor： Toni WEINSCHENK ,  Steffen WALTER ,  Jens FRITSCHE ,  Colette SONG ,  Harpreet SINGH

IPC: C07K7/08 ,  A61K35/17 ,  A61K38/17 ,  A61K39/00 ,  A61K45/06 ,  C07K7/06 ,  C07K14/725 ,  C12N5/0783 ,  C12N9/64

Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.

公开(公告)号：US20230338489A1

公开(公告)日：2023-10-26

申请号：US18323577

申请日：2023-05-25

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C07K7/08 ,  C12N15/115 ,  C12N5/0783 ,  C07K14/71 ,  C07K14/725 ,  C07K16/28 ,  C12Q1/6886 ,  C07K16/18 ,  G01N33/574 ,  C07K14/47 ,  C07K16/30 ,  C07K7/06 ,  C07K14/72 ,  C12N9/12 ,  C07K16/38 ,  C07K14/81 ,  C07K16/40 ,  C12N9/02 ,  C07K14/705 ,  G16B25/00 ,  G16B25/10

CPC classification number: A61K39/0011 ,  C07K7/08 ,  C12N15/115 ,  C12N5/0638 ,  C07K14/71 ,  C07K14/7051 ,  C07K16/2863 ,  C12Q1/6886 ,  C07K16/18 ,  G01N33/57484 ,  C07K14/4748 ,  C07K16/30 ,  C07K7/06 ,  C12N5/0636 ,  C07K16/2869 ,  C07K14/721 ,  C12Y207/07031 ,  C12N9/1264 ,  C07K16/38 ,  C07K14/8135 ,  C07K14/47 ,  C12Y116/01 ,  C07K16/40 ,  C12N9/0091 ,  C07K14/705 ,  C07K16/28 ,  G16B25/00 ,  G16B25/10 ,  C07K2319/40 ,  A61K35/17

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230148369A1

公开(公告)日：2023-05-11

申请号：US17820821

申请日：2022-08-18

Applicant: Immatics Biotechnologies GmbH

Inventor： Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH

IPC: C07K14/47 ,  A61P35/00 ,  A61K39/00 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/10 ,  C12N15/115 ,  G01N33/574 ,  A61K35/17 ,  C07K7/06 ,  C07K14/54

CPC classification number: C07K14/4748 ,  A61P35/00 ,  A61K39/001102 ,  A61K39/0011 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/2818 ,  C07K16/30 ,  C12N5/0638 ,  C12N15/1062 ,  C12N15/115 ,  G01N33/57492 ,  A61K35/17 ,  C07K7/06 ,  C07K14/5434 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K2319/00 ,  C12N2501/50 ,  A61K38/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230094553A1

公开(公告)日：2023-03-30

申请号：US17822653

申请日：2022-08-26

Applicant: Immatics Biotechnologies GmbH

Inventor： Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH

IPC: C07K14/47 ,  A61P35/00 ,  A61K39/00 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/10 ,  C12N15/115 ,  G01N33/574 ,  A61K35/17 ,  C07K7/06 ,  C07K14/54

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230089882A1

公开(公告)日：2023-03-23

申请号：US17851417

申请日：2022-06-28

Applicant: Immatics Biotechnologies GmbH

Inventor： Sabrina KUTTRUFF-COQUI ,  Toni WEINSCHENK ,  Jens FRITSCHE ,  Steffen WALTER ,  Norbert HILF ,  Oliver SCHOOR ,  Colette SONG ,  Harpreet SINGH

IPC: A61K39/00 ,  C07K14/47 ,  C07K14/705 ,  A61K35/17 ,  C07K7/06 ,  C07K7/08 ,  C07K14/74 ,  C07K16/28 ,  C12Q1/6886

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

公开(公告)号：US20230042253A1

公开(公告)日：2023-02-09

申请号：US17934747

申请日：2022-09-23

Applicant: Immatics Biotechnologies GmbH

Inventor： Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH

IPC: C07K14/47 ,  C07K7/06 ,  C07K14/725 ,  A61K35/17 ,  C07K14/74 ,  C07K16/30 ,  C07K16/28 ,  C12N15/10 ,  A61K39/00 ,  C07K14/54 ,  G01N33/574 ,  C12N5/0783 ,  C12N15/115 ,  A61P35/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230040789A1

公开(公告)日：2023-02-09

申请号：US17843733

申请日：2022-06-17

Applicant: Immatics Biotechnologies GmbH

Inventor： Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH

IPC: C07K14/47 ,  A61K35/17 ,  C07K14/725 ,  C12N15/115 ,  G01N33/574 ,  C12N15/10 ,  C07K16/28 ,  C07K14/74 ,  C07K16/30 ,  C12N5/0783 ,  A61K39/00 ,  C07K7/06 ,  A61P35/00 ,  C07K14/54 ,  A61K38/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230023408A1

公开(公告)日：2023-01-26

申请号：US17930969

申请日：2022-09-09

Applicant: Immatics Biotechnologies GmbH

Inventor： Colette SONG ,  Heiko SCHUSTER ,  Daniel Johannes KOWALEWSKI ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH

IPC: C07K14/47 ,  A61K35/17 ,  A61K39/00 ,  C07K14/725 ,  C07K14/74 ,  C07K16/18 ,  C12N5/0783 ,  C12Q1/6886

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230021673A1

公开(公告)日：2023-01-26

申请号：US17822657

申请日：2022-08-26

Applicant: Immatics Biotechnologies GmbH

Inventor： Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH

IPC: C07K14/47 ,  C07K7/06 ,  C07K14/725 ,  A61K35/17 ,  C07K14/74 ,  C07K16/30 ,  C07K16/28 ,  C12N15/10 ,  A61K39/00 ,  C07K14/54 ,  G01N33/574 ,  C12N5/0783 ,  C12N15/115 ,  A61P35/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220363730A1

公开(公告)日：2022-11-17

申请号：US17877515

申请日：2022-07-29

Applicant: Immatics Biotechnologies GmbH

Inventor： Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH

IPC: C07K14/47 ,  C12N15/10 ,  C07K16/30 ,  C07K7/06 ,  G01N33/574 ,  A61K35/17 ,  C12N15/115 ,  C07K14/54 ,  C07K14/74 ,  C07K16/28 ,  A61K39/00 ,  C07K14/725 ,  C12N5/0783 ,  A61P35/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.